ZERO PRAISE FROM ME Bristol Myers Squibb funded research. Bristol Myers Squibb (NYSE:BMY) today announced that Orencia® (abatacept) was approved by the U.S. F

ZERO PRAISE FROM ME Bristol Myers Squibb funded research. Bristol Myers Squibb (NYSE:BMY) today announced that Orencia® (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis, or prevention, of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor (URD).2 No mention of rheumatoid arthritis prevention there, only autoimmune disorders And stem cell transplants. No mention of Bristol Myers Squibb funding by Birmingham ac: I always find it amazing that reading an article about some recent research seems to skimp on the important stuff. Adverse effects: People have experienced serious infections due to abatacept's suppression of the immune system; some of these infections have been fatal. People with COPD are likely to get lung infections more often than usual. Some people have had anaphylactic reactions to the drug. Abatacept may cause otherwise slow-growing cancers to proliferate and spread, due to suppression of the immune system.[5] Very common adverse effects (occurring in more than 10% of people) include upper respiratory tract infections. Common adverse effects (occurring in between 1% and 10% of people) include lower respiratory tract infections, urinary tract infections, herpes infections, pneumonia, flu, cough, high blood pressure, stomach pain, diarrhea, nausea, vomiting, upset stomach, mouth sores, elevated transaminases, rashes, fatigue, weakness, local injection site reactions, and systemic injection reactions.[5] Sounds like they copied that from covid jab adverse events document.